Evidence map›Paper›PMID 30359340›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Silence of Stomatin-Like Protein 2 Represses Migration and Invasion Ability of Human Liver Cancer Cells via Inhibiting the Nuclear Factor Kappa B (NF-κB) Pathway.

Wenyu Zhu, Wei Li, Qian Geng, Xiaoying Wang, Wei Sun, Hua Jiang, Xiaolin Pu

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Wenyu ZhuDepartment of Oncology, The Affiliated Changzhou No. 2 People's Hospital with Nanjing Medical University, Changzhou, Jiangsu, China (mainland).
Wei LiDepartment of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China (mainland).
Qian GengDepartment of Oncology, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, Changzhou, Jiangsu, China (mainland).
Xiaoying WangDepartment of Oncology, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, , China (mainland).
Wei SunDepartment of Oncology, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, Changzhou, Jiangsu, China (mainland).
Hua JiangDepartment of Oncology, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, Changzhou, Jiangsu, China (mainland).
Xiaolin PuDepartment of Oncology, The Affiliated Changzhou No.2 People's Hospital with Nanjing Medical University, Changzhou, Jiangsu, China (mainland).
Changzhou No.2 People's Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Liver cancer is the third leading cause of tumor-related deaths worldwide. Stomatin-like protein 2 (STOML2) is obviously upregulated in various tumors. In this study, we explored the potential roles and mechanisms of si-STOML2 in the migration and invasion of human hepatoma LM3 cells. MATERIAL AND METHODS The expression levels of STOML2 in tissues and cells were separately analyzed with quantitative real-time PCR (qRT-PCR) and Western blotting. The viability, migration, and invasion of cells were assessed by cell counting kit-8 (CCK-8), wound healing, and transwell analysis, respectively. The mRNA and protein levels of various factors were separately measured using qRT-PCR and Western blotting. Correlation analysis between the expression of STOML2 and the clinicopathological features of liver cancer patients was evaluated using the chi-square test. RESULTS Surprisingly, our results showed that STOML2 was upregulated in liver cancer tissue and cells, and this upregulation was linked to tumor size, histologic grade, and metastasis, but was not associated with sex, age, or TNM stage. The knockdown of STOML2 significantly repressed the viability, migration, and invasion of LM3 cells. We also observed that silencing STOML2 markedly downregulated the expression levels of matrix metalloproteinase-2 (MMP-2), MMP-9, metastatic tumor antigen 1 (MTA1), and nuclear factor kappa B (NF-κB), and upregulated levels of E-cadherin, tissue inhibitor of metalloproteinases 2 (TIMP2), and the inhibitor of kappa B (IκB). CONCLUSIONS STOML2 has a vital role in the progression of liver cancer. STOML2 silencing in LM3 cells obviously repressed the abilities of migration and invasion via suppressing the NF-κB pathway.

Indexed as

AdultAgedBlood ProteinsCadherinsCarcinoma, HepatocellularCell Line, TumorCell MovementCell ProliferationFemaleHistone DeacetylasesHumansLiver NeoplasmsMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9Membrane ProteinsBlood ProteinsCadherinsHistone DeacetylasesMatrix Metalloproteinase 2Matrix Metalloproteinase 9Membrane ProteinsMMP2 protein, humanMMP9 protein, humanMTA1 protein, humanNF-kappa BRepressor ProteinsSTOML2 protein, humanTIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2Trans-Activators

Identifiers

PMID30359340
PMCPMC6213821
OpenAlexW2898306334

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.